Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 667

1.

Cortical abnormalities in episodic migraine: A multi-center 3T MRI study.

Magon S, May A, Stankewitz A, Goadsby PJ, Schankin C, Ashina M, Amin FM, Seifert CL, Mallar Chakravarty M, Müller J, Sprenger T.

Cephalalgia. 2018 Dec 10:333102418795163. doi: 10.1177/0333102418795163. [Epub ahead of print]

PMID:
30525946
2.

Biological insights from the premonitory symptoms of migraine.

Karsan N, Goadsby PJ.

Nat Rev Neurol. 2018 Dec;14(12):699-710. doi: 10.1038/s41582-018-0098-4. Review.

PMID:
30448858
3.

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.

Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK.

Neurology. 2018 Dec 11;91(24):e2211-e2221. doi: 10.1212/WNL.0000000000006640. Epub 2018 Nov 16.

PMID:
30446596
4.

Divergent influences of the locus coeruleus on migraine pathophysiology.

Vila-Pueyo M, Strother LC, Kefel M, Goadsby PJ, Holland PR.

Pain. 2018 Oct 26. doi: 10.1097/j.pain.0000000000001421. [Epub ahead of print]

PMID:
30371556
5.

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.

Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J.

Lancet. 2018 Nov 24;392(10161):2280-2287. doi: 10.1016/S0140-6736(18)32534-0. Epub 2018 Oct 22.

PMID:
30360965
6.

Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents.

Szperka CL, VanderPluym J, Orr SL, Oakley CB, Qubty W, Patniyot I, Lagman-Bartolome AM, Morris C, Gautreaux J, Victorio MC, Hagler S, Narula S, Candee MS, Cleves-Bayon C, Rao R, Fryer RH, Bicknese AR, Yonker M, Hershey AD, Powers SW, Goadsby PJ, Gelfand AA.

Headache. 2018 Nov;58(10):1658-1669. doi: 10.1111/head.13414. Epub 2018 Oct 15. No abstract available.

PMID:
30324723
7.

Prolonged migraine aura: new insights from a prospective diary-aided study.

Viana M, Sances G, Linde M, Nappi G, Khaliq F, Goadsby PJ, Tassorelli C.

J Headache Pain. 2018 Aug 31;19(1):77. doi: 10.1186/s10194-018-0910-y.

8.

The Migraine Postdrome.

Bose P, Karsan N, Goadsby PJ.

Continuum (Minneap Minn). 2018 Aug;24(4, Headache):1023-1031. doi: 10.1212/CON.0000000000000626.

PMID:
30074547
9.

The Migraine Premonitory Phase.

Karsan N, Bose P, Goadsby PJ.

Continuum (Minneap Minn). 2018 Aug;24(4, Headache):996-1008. doi: 10.1212/CON.0000000000000624.

PMID:
30074545
10.

Identifying Natural Subgroups of Migraine Based on Comorbidity and Concomitant Condition Profiles: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.

Lipton RB, Fanning KM, Buse DC, Martin VT, Reed ML, Manack Adams A, Goadsby PJ.

Headache. 2018 Jul;58(7):933-947. doi: 10.1111/head.13342. Epub 2018 Jul 19.

PMID:
30024028
11.

Cluster Headache and Calcitonin Gene-Related Peptide-More on Quantum Therapeutics in Headache Medicine.

Gelfand AA, Goadsby PJ.

JAMA Neurol. 2018 Oct 1;75(10):1179-1180. doi: 10.1001/jamaneurol.2018.1428. No abstract available.

PMID:
29987331
12.

Recent advances in headache neuroimaging.

Messina R, Filippi M, Goadsby PJ.

Curr Opin Neurol. 2018 Aug;31(4):379-385. doi: 10.1097/WCO.0000000000000573.

PMID:
29952833
13.

Gray matter volume modifications in migraine: A cross-sectional and longitudinal study.

Messina R, Rocca MA, Colombo B, Pagani E, Falini A, Goadsby PJ, Filippi M.

Neurology. 2018 Jul 17;91(3):e280-e292. doi: 10.1212/WNL.0000000000005819. Epub 2018 Jun 20.

PMID:
29925551
14.

Comment: Noninvasive neurostimulation for migraine should be part of the general neurologist's therapeutic armamentarium.

Lipton RB, Goadsby PJ.

Neurology. 2018 Jul 24;91(4):167. doi: 10.1212/WNL.0000000000005870. Epub 2018 Jun 15. No abstract available.

PMID:
29907607
15.

Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members' View in an AIP Mutation-Positive Family.

Marques P, Barry S, Ronaldson A, Ogilvie A, Storr HL, Goadsby PJ, Powell M, Dang MN, Chahal HS, Evanson J, Kumar AV, Grieve J, Korbonits M.

Int J Endocrinol. 2018 Apr 4;2018:8581626. doi: 10.1155/2018/8581626. eCollection 2018.

16.

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.

Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.

JAMA. 2018 May 15;319(19):1999-2008. doi: 10.1001/jama.2018.4853.

PMID:
29800211
17.

Overview of Trigeminal Autonomic Cephalalgias: Nosologic Evolution, Diagnosis, and Management.

Wei DY, Yuan Ong JJ, Goadsby PJ.

Ann Indian Acad Neurol. 2018 Apr;21(Suppl 1):S39-S44. doi: 10.4103/aian.AIAN_348_17. Review.

18.

Cluster Headache: Epidemiology, Pathophysiology, Clinical Features, and Diagnosis.

Wei DY, Yuan Ong JJ, Goadsby PJ.

Ann Indian Acad Neurol. 2018 Apr;21(Suppl 1):S3-S8. doi: 10.4103/aian.AIAN_349_17. Review.

19.

Migraine Therapy: Current Approaches and New Horizons.

Goadsby PJ, Holland PR.

Neurotherapeutics. 2018 Apr;15(2):271-273. doi: 10.1007/s13311-018-0626-3. No abstract available.

PMID:
29667112
20.

CGRP - a target for acute therapy in migraine: Clinical data.

Messina R, Goadsby PJ.

Cephalalgia. 2018 Jan 1:333102418768095. doi: 10.1177/0333102418768095. [Epub ahead of print]

PMID:
29616830
21.

Migraine is common in patients with sarcoidosis.

Gelfand JM, Gelfand AA, Goadsby PJ, Benn BS, Koth LL.

Cephalalgia. 2018 Dec;38(14):2079-2082. doi: 10.1177/0333102418768037. Epub 2018 Mar 26.

PMID:
29580067
22.

Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.

Holland PR, Goadsby PJ.

Neurotherapeutics. 2018 Apr;15(2):304-312. doi: 10.1007/s13311-018-0617-4. Review.

23.

Transcranial Magnetic Stimulation for Migraine Prevention in Adolescents: A Pilot Open-Label Study.

Irwin SL, Qubty W, Allen IE, Patniyot I, Goadsby PJ, Gelfand AA.

Headache. 2018 May;58(5):724-731. doi: 10.1111/head.13284. Epub 2018 Mar 12.

PMID:
29528485
24.

Flunarizine in migraine-related headache prevention: results from 200 patients treated in the UK.

Karsan N, Palethorpe D, Rattanawong W, Marin JC, Bhola R, Goadsby PJ.

Eur J Neurol. 2018 Jun;25(6):811-817. doi: 10.1111/ene.13621. Epub 2018 Apr 11.

PMID:
29512871
25.

A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study).

Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, Charles AC, Goadsby PJ, Lipton RB, Silberstein SD, Gelfand AA, Chiacchierini RP, Dodick DW.

Cephalalgia. 2018 May;38(6):1038-1048. doi: 10.1177/0333102418762525. Epub 2018 Mar 4.

26.

Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults.

Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ; International Headache Society Clinical Trials Standing Committee.

Cephalalgia. 2018 Apr;38(5):815-832. doi: 10.1177/0333102418758283. Epub 2018 Mar 4.

PMID:
29504482
27.

Preventive Therapies for Chronic Migraine.

Goadsby PJ, Picard H, Mikol DD.

N Engl J Med. 2018 Feb 22;378(8):774-5. doi: 10.1056/NEJMc1716990. No abstract available.

PMID:
29469553
28.

Case Report of the Safety Assessment of Transcranial Magnetic Stimulation Use in a Patient With Cardiac Pacemaker: To Pulse or Not to Pulse?

Wei DY, Greenwood FS, Murgatroyd FD, Goadsby PJ.

Headache. 2018 Feb;58(2):295-297. doi: 10.1111/head.13258.

PMID:
29411366
29.

Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Ong JJY, Wei DY, Goadsby PJ.

Drugs. 2018 Mar;78(4):411-437. doi: 10.1007/s40265-018-0865-y. Review.

PMID:
29396834
30.
31.

Experts' opinion about the pediatric secondary headaches diagnostic criteria of the ICHD-3 beta.

Özge A, Abu-Arafeh I, Gelfand AA, Goadsby PJ, Cuvellier JC, Valeriani M, Sergeev A, Barlow K, Uludüz D, Yalın OÖ, Faedda N, Lipton RB, Rapoport A, Guidetti V.

J Headache Pain. 2017 Nov 29;18(1):113. doi: 10.1186/s10194-017-0819-x.

32.

Experts' opinion about the primary headache diagnostic criteria of the ICHD-3rd edition beta in children and adolescents.

Özge A, Faedda N, Abu-Arafeh I, Gelfand AA, Goadsby PJ, Cuvellier JC, Valeriani M, Sergeev A, Barlow K, Uludüz D, Yalın OÖ, Lipton RB, Rapoport A, Guidetti V.

J Headache Pain. 2017 Nov 23;18(1):109. doi: 10.1186/s10194-017-0818-y. Review.

33.

Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.

Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, Johnson KW, Shan Q, Carter J, Schacht A, Goadsby PJ, Dodick DW.

JAMA Neurol. 2018 Feb 1;75(2):187-193. doi: 10.1001/jamaneurol.2017.3859.

34.

Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study.

Goadsby PJ, de Coo IF, Silver N, Tyagi A, Ahmed F, Gaul C, Jensen RH, Diener HC, Solbach K, Straube A, Liebler E, Marin JC, Ferrari MD; ACT2 Study Group.

Cephalalgia. 2018 Apr;38(5):959-969. doi: 10.1177/0333102417744362. Epub 2017 Dec 12.

35.

A Controlled Trial of Erenumab for Episodic Migraine.

Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA.

N Engl J Med. 2017 Nov 30;377(22):2123-2132. doi: 10.1056/NEJMoa1705848.

PMID:
29171821
36.

Fremanezumab for the Preventive Treatment of Chronic Migraine.

Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.

N Engl J Med. 2017 Nov 30;377(22):2113-2122. doi: 10.1056/NEJMoa1709038.

PMID:
29171818
37.

Visual snow syndrome: what we know so far.

Puledda F, Schankin C, Digre K, Goadsby PJ.

Curr Opin Neurol. 2018 Feb;31(1):52-58. doi: 10.1097/WCO.0000000000000523. Review.

PMID:
29140814
38.

Phenotypic and treatment outcome data on SUNCT and SUNA, including a randomised placebo-controlled trial.

Weng HY, Cohen AS, Schankin C, Goadsby PJ.

Cephalalgia. 2018 Aug;38(9):1554-1563. doi: 10.1177/0333102417739304. Epub 2017 Nov 2.

39.

Cluster headache and the trigeminal-autonomic reflex: Driving or being driven?

Goadsby PJ.

Cephalalgia. 2018 Jul;38(8):1415-1417. doi: 10.1177/0333102417738252. Epub 2017 Oct 30. No abstract available.

PMID:
29082825
40.

Noninvasive Vagus Nerve Stimulation for Treatment of Indomethacin-Sensitive Headaches.

Tso AR, Marin J, Goadsby PJ.

JAMA Neurol. 2017 Oct 1;74(10):1266-1267. doi: 10.1001/jamaneurol.2017.2122. No abstract available.

41.

Comparative effects of traditional Chinese and Western migraine medicines in an animal model of nociceptive trigeminovascular activation.

Zhao Y, Martins-Oliveira M, Akerman S, Goadsby PJ.

Cephalalgia. 2018 Jun;38(7):1215-1224. doi: 10.1177/0333102417728245. Epub 2017 Aug 24. Erratum in: Cephalalgia. 2018 Jun;38(7):NP1.

42.

Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.

Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA.

Neurology. 2017 Sep 19;89(12):1237-1243. doi: 10.1212/WNL.0000000000004391. Epub 2017 Aug 23.

PMID:
28835404
43.

Re: Placebo responses in device studies.

Goadsby PJ, Dodick DW, Lipton RB.

Cephalalgia. 2018 Apr;38(5):1007-1008. doi: 10.1177/0333102417722498. Epub 2017 Jul 26. No abstract available.

PMID:
28747062
44.

Occipital headaches and neuroimaging in children.

Bear JJ, Gelfand AA, Goadsby PJ, Bass N.

Neurology. 2017 Aug 1;89(5):469-474. doi: 10.1212/WNL.0000000000004186. Epub 2017 Jun 30.

45.

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?

Tso AR, Goadsby PJ.

Curr Treat Options Neurol. 2017 Aug;19(8):27. doi: 10.1007/s11940-017-0463-4. Review.

46.

Premonitory Symptoms of Migraine in Childhood and Adolescence.

Karsan N, Prabhakar P, Goadsby PJ.

Curr Pain Headache Rep. 2017 Jul;21(7):34. doi: 10.1007/s11916-017-0631-y. Review.

47.

Pediatric Migraine Prevention-First, Do No Harm.

Gelfand AA, Qubty W, Goadsby PJ.

JAMA Neurol. 2017 Aug 1;74(8):893-894. doi: 10.1001/jamaneurol.2017.1011. No abstract available.

PMID:
28628697
48.

Increased rate of venous thrombosis may be associated with inpatient dihydroergotamine treatment.

Tso AR, Patniyot IR, Gelfand AA, Goadsby PJ.

Neurology. 2017 Jul 18;89(3):279-283. doi: 10.1212/WNL.0000000000004108. Epub 2017 Jun 14.

49.

Author response: Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache.

Robbins NM, Goadsby PJ.

Neurology. 2017 May 30;88(22):2156. doi: 10.1212/WNL.0000000000004000. No abstract available.

PMID:
28554903
50.

Home-Based Trials in Adolescent Migraine: A Randomized Clinical Trial.

Gelfand AA, Qubty W, Patniyot I, Grimes B, Pletcher MJ, Goadsby PJ, Cummings SR.

JAMA Neurol. 2017 Jun 1;74(6):744-745. doi: 10.1001/jamaneurol.2017.0285. No abstract available.

Supplemental Content

Loading ...
Support Center